Neuroectodermal Tumors Completed Phase 2 Trials for DB12250 (Cixutumumab)

Also known as: Neuroectodermal Tumor

IndicationStatusPhase
DBCOND0040519 (Neuroectodermal Tumors)Completed2
clinicaltrials.gov IdentifierTitlePurposeDrugs
NCT00831844Cixutumumab in Treating Patients With Relapsed or Refractory Solid TumorsTreatment